Thrivent Financial for Lutherans Purchases 514,542 Shares of Sanofi (NASDAQ:SNY)

Thrivent Financial for Lutherans raised its stake in shares of Sanofi (NASDAQ:SNY) by 36.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,943,761 shares of the company’s stock after purchasing an additional 514,542 shares during the quarter. Thrivent Financial for Lutherans owned about 0.08% of Sanofi worth $93,774,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Synergy Asset Management LLC acquired a new position in Sanofi during the 4th quarter valued at approximately $25,000. McClarren Financial Advisors Inc. increased its stake in Sanofi by 952.6% during the 4th quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock valued at $28,000 after purchasing an additional 543 shares in the last quarter. Sunbelt Securities Inc. increased its stake in shares of Sanofi by 72.1% in the third quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock worth $43,000 after acquiring an additional 313 shares during the period. Sierra Ocean LLC acquired a new stake in shares of Sanofi in the fourth quarter worth $44,000. Finally, Versant Capital Management Inc acquired a new stake in shares of Sanofi in the fourth quarter worth $54,000. Institutional investors and hedge funds own 14.04% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on SNY shares. StockNews.com lowered shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Finally, Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. Two investment analysts have rated the stock with a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $60.00.

Sanofi Stock Performance

Shares of NASDAQ SNY opened at $59.11 on Wednesday. The company’s fifty day moving average price is $54.03 and its 200 day moving average price is $52.85. Sanofi has a 1 year low of $45.22 and a 1 year high of $60.12. The company has a market capitalization of $150.01 billion, a PE ratio of 23.74, a price-to-earnings-growth ratio of 1.01 and a beta of 0.58. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. On average, research analysts predict that Sanofi will post 4.36 earnings per share for the current year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.